Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly FCF Margin of 880.53% for Q3 2021, up 309972.0% year-over-year from N/an in Q3 2020, and up 106.86% quarter-over-quarter from 12835.99% in Q2 2021.
Corbus Pharmaceuticals Holdings (CRBP) FCF Margin (2015 - 2021) Analysis & Trends
Corbus Pharmaceuticals Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 880.53% for Q3 2021.
- In Q3 2021, FCF Margin rose 309972.0% year-over-year to 880.53%; the TTM figure through Jun 2022 stood at 32631.18% (down 3036082.0% YoY), while the FY2021 annual figure was 5470.98%, down 346757.0% from the prior year.
- FCF Margin for Q3 2021 stood at 880.53%, up from 12835.99% in the prior quarter.
- The five-year high for FCF Margin was 880.53% in Q3 2021, with the low at 12835.99% in Q2 2021.
- The 5-year median for FCF Margin is 771.78% (2018), against an average of 1954.41%.
- The sharpest annual moves came in 2020 and 2021: FCF Margin sank 924062 bps in 2020, then jumped 309972 bps in 2021.
- Corbus Pharmaceuticals Holdings' FCF Margin stood at 800.85% in 2017, then gained by 7 bps to 742.7% in 2018, then jumped by 111 bps to 83.49% in 2019, then tumbled by 1365 bps to 1055.93% in 2020, then jumped by 183 bps to 880.53% in 2021.
- Business Quant data shows CRBP's FCF Margin at 880.53% in Q3 2021, 12835.99% in Q2 2021, and 3366.58% in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 880.53% |
| Jun 30, 2021 | -12,835.99% |
| Mar 31, 2021 | -3,366.58% |
| Dec 31, 2020 | -1,055.93% |
| Sep 30, 2020 | -2,219.20% |
| Jun 30, 2020 | -9,297.60% |
| Mar 31, 2020 | -1,592.73% |
| Dec 31, 2019 | 83.49% |
| Sep 30, 2019 | -705.78% |
| Jun 30, 2019 | -56.97% |
| Mar 31, 2019 | 543.29% |
| Dec 31, 2018 | -742.70% |
| Sep 30, 2018 | -820.69% |
| Jun 30, 2018 | -730.02% |
| Mar 31, 2018 | -301.86% |
| Sep 30, 2017 | -800.85% |
| Jun 30, 2017 | -1,643.80% |
| Mar 31, 2017 | -516.06% |
| Sep 30, 2016 | -420.29% |
| Jun 30, 2016 | -655.84% |